Autopsy report · NCT00662740
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
Cause of deathNo reason given
Life of this trial
- Ran for about 7 months before it stopped.
- 220 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium/Salmeterol QD; Placebo; Salmeterol; Tiotropium/Salmeterol QD+ Salmeterol; Tiotropium (Spiriva®)
- Participants
- 220
- Sites
- 72
- Countries
- Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.